Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a primary myocardial disease characterized by impaired diastolic filling of the ventricles due to increased myocardial stiffness, with normal or near-normal systolic function and without significant ventricular dilation or hypertrophy. In veterinary medicine, RCM is most commonly recognized in cats, where it is one of the three main forms of cardiomyopathy (the others being hypertrophic cardiomyopathy [HCM] and dilated cardiomyopathy [DCM]). The hallmark is severe diastolic dysfunction leading to elevated ventricular filling pressures, atrial enlargement, and a propensity for congestive heart failure (CHF) and arterial thromboembolism (ATE). The disease is classified into two main forms: myocardial (primary) RCM, where the myocardium itself is stiff, and endomyocardial (secondary) RCM, where fibrosis or other infiltrative processes affect the endocardium and subendocardium. In cats, RCM is often idiopathic, but it can also be secondary to infiltrative diseases such as amyloidosis or endomyocardial fibrosis. The condition is progressive and carries a guarded to poor long-term prognosis, with median survival times ranging from 1 to 2 years after diagnosis, depending on the presence of CHF or ATE.

The exact etiology of primary restrictive cardiomyopathy in cats is largely unknown, but it is believed to be a primary myocardial disorder, possibly with a genetic basis, although no specific gene mutations have been identified as consistently as in HCM. Secondary causes include infiltrative myocardial diseases such as cardiac amyloidosis (particularly in Siamese and Abyssinian cats), endomyocardial fibrosis (which can be idiopathic or secondary to chronic inflammation), and rarely, neoplastic infiltration (e.g., lymphoma). In dogs, RCM is extremely rare, but it can occur secondary to endomyocardial fibrosis, which has been reported in certain breeds (e.g., Boxers) and may be associated with chronic inflammatory or immune-mediated processes. Other potential etiologies include radiation-induced myocardial fibrosis, toxic exposures (e.g., doxorubicin), and nutritional deficiencies (e.g., taurine deficiency, though this more commonly causes DCM). In some cases, RCM may be a sequela of chronic myocarditis, leading to diffuse myocardial fibrosis. The molecular mechanisms involve increased collagen deposition, myocyte hypertrophy, and interstitial fibrosis, which increase myocardial stiffness and impair relaxation and filling.

Restrictive cardiomyopathy is predominantly a disease of cats, with a higher prevalence in middle-aged to older cats (median age around 7-10 years). There is no strong sex predilection, though some studies suggest a slight male predominance. Certain breeds, such as the Siamese, Burmese, and Abyssinian, may be overrepresented, possibly due to genetic predisposition. In dogs, RCM is exceedingly rare and is reported sporadically, with no clear breed or age predilection, although endomyocardial fibrosis has been described in young Boxers. The overall incidence in the general feline population is estimated to be around 5-10% of all cardiomyopathies, making it the third most common feline cardiomyopathy after HCM and DCM. Geographic variation is not well-documented, but cardiac amyloidosis, a cause of RCM, is more common in certain breeds and may have regional clustering. The disease is typically acquired, with no known seasonal or environmental triggers, except for secondary causes such as toxin exposure or infectious agents that may lead to myocarditis and subsequent fibrosis.

The pathophysiology of restrictive cardiomyopathy centers on diastolic dysfunction. The primary defect is increased myocardial stiffness, which impairs ventricular relaxation and filling during diastole. This leads to elevated end-diastolic pressures in the ventricles, which in turn cause atrial enlargement and increased pulmonary venous and systemic venous pressures. The atria dilate and hypertrophy in response to the pressure overload, and this predisposes to atrial fibrillation and the formation of thrombi, particularly in the left atrium, which can embolize to the systemic circulation, most commonly causing aortic thromboembolism (saddle thrombus). Systolic function is typically preserved in the early stages, but as the disease progresses, some cats may develop mild to moderate systolic dysfunction. The restrictive physiology is often characterized by a restrictive filling pattern on Doppler echocardiography, with a short E-wave deceleration time, increased E/A ratio, and decreased tissue Doppler velocities. The myocardial stiffness can be due to interstitial fibrosis, myocyte hypertrophy, or infiltration by amyloid or other substances. In endomyocardial fibrosis, the fibrotic process primarily affects the endocardium and subendocardium, leading to obliteration of the ventricular apex and impaired filling. The elevated filling pressures eventually lead to congestive heart failure, with pulmonary edema and pleural effusion being common manifestations. Additionally, the chronic pressure overload can lead to secondary mitral and tricuspid regurgitation due to annular dilation, further exacerbating atrial enlargement.

Predisposing factors for restrictive cardiomyopathy include genetic predisposition, particularly in certain feline breeds (Siamese, Burmese, Abyssinian) and possibly in Boxer dogs. Age is a significant factor, as the disease is more common in middle-aged to older cats. Sex may play a minor role, with a slight male predominance in some studies. Secondary causes such as cardiac amyloidosis are more common in certain breeds (e.g., Abyssinian and Siamese cats) and may be influenced by genetic factors. Chronic hypertension, hyperthyroidism, and acromegaly can exacerbate diastolic dysfunction and may contribute to the development of RCM in predisposed individuals. Toxin exposure (e.g., doxorubicin) and nutritional deficiencies (e.g., taurine deficiency) are rare but potential causes. Concurrent diseases such as chronic kidney disease or diabetes mellitus may worsen the clinical course. Environmental factors are not well-defined, but stress and obesity may exacerbate clinical signs. Immunosuppression or chronic inflammatory conditions may predispose to myocarditis, which can progress to fibrosis and RCM.

Clinical signs of restrictive cardiomyopathy are often insidious and may be absent in the early stages. When present, they are primarily related to congestive heart failure and thromboembolism. Common signs include lethargy, anorexia, weight loss, and exercise intolerance. Respiratory signs such as tachypnea, dyspnea, and coughing (though coughing is less common in cats) may indicate pulmonary edema or pleural effusion. Cats may present with acute onset of dyspnea due to CHF or with acute hindlimb paralysis due to aortic thromboembolism (saddle thrombus). Physical examination findings may include a heart murmur (often a soft systolic murmur due to mitral regurgitation), gallop rhythm (S3 or S4), and arrhythmias. In cases of pleural effusion, lung sounds may be muffled ventrally. With ATE, the affected limbs are cold, painful, and pulseless, with absent femoral pulses and cyanotic nail beds. In chronic cases, cachexia and muscle wasting may be evident. The clinical course can be divided into stages: asymptomatic (occult) stage, symptomatic stage with CHF, and terminal stage with refractory CHF or recurrent thromboembolism.

Differential diagnoses for restrictive cardiomyopathy include other cardiomyopathies, particularly hypertrophic cardiomyopathy (HCM), which also causes diastolic dysfunction but is characterized by concentric left ventricular hypertrophy. Dilated cardiomyopathy (DCM) is characterized by systolic dysfunction and ventricular dilation, which is not typical of RCM. Unclassified cardiomyopathy (UCM) may have features of multiple cardiomyopathies. Other differentials include congenital heart diseases (e.g., mitral valve dysplasia), pericardial diseases (e.g., pericardial effusion, constrictive pericarditis), and systemic diseases that affect the heart, such as hyperthyroidism, systemic hypertension, and acromegaly. Infiltrative diseases like cardiac lymphoma or amyloidosis can mimic RCM. Endocarditis and myocarditis may also cause similar clinical signs. Key distinguishing features include echocardiographic findings: HCM shows left ventricular wall thickening, DCM shows dilation and poor systolic function, and RCM shows normal wall thickness and systolic function but with severe atrial enlargement and restrictive filling pattern. Pericardial disease is differentiated by the presence of pericardial effusion or thickening on echocardiography. Hyperthyroidism is ruled out by serum T4 measurement, and hypertension by blood pressure measurement.

The diagnostic algorithm for restrictive cardiomyopathy begins with a thorough history and physical examination, with particular attention to cardiac auscultation (murmur, gallop), respiratory effort, and femoral pulses. If cardiac disease is suspected, the next step is thoracic radiography to assess for cardiomegaly, pulmonary edema, and pleural effusion. Echocardiography is the gold standard for diagnosis and should be performed in all suspected cases. The echocardiogram should include 2D, M-mode, and Doppler studies to evaluate left atrial size, left ventricular wall thickness and systolic function, and diastolic function (mitral inflow velocities, tissue Doppler imaging). A restrictive filling pattern (E/A > 2, short deceleration time) is characteristic. If echocardiography is inconclusive, advanced imaging such as cardiac MRI may be considered, but it is rarely used in veterinary practice. Blood tests, including complete blood count, serum biochemistry, and thyroid hormone levels, are recommended to rule out secondary causes. Cardiac biomarkers such as NT-proBNP and troponin I can support the diagnosis and help assess prognosis. In cases where a specific etiology is suspected (e.g., amyloidosis), histopathology via endomyocardial biopsy may be performed, but this is rarely done due to the risks. The diagnostic algorithm should also include screening for thromboembolism, such as echocardiographic assessment for left atrial thrombi and Doppler evaluation of the aorta.

Laboratory findings in restrictive cardiomyopathy are often nonspecific but may reflect the presence of congestive heart failure or concurrent diseases. Complete blood count may show stress leukogram or hemoconcentration in cases of dehydration. Serum biochemistry may reveal elevated liver enzymes (ALT, ALP) due to hepatic congestion, elevated BUN and creatinine due to decreased renal perfusion or concurrent chronic kidney disease, and electrolyte imbalances (e.g., hypokalemia) due to diuretic therapy. Cardiac biomarkers: NT-proBNP is often elevated (typically > 100 pmol/L in cats with cardiac disease) and can help differentiate cardiac from non-cardiac causes of respiratory signs. Troponin I may be elevated due to myocardial injury. In cases of thromboembolism, there may be evidence of muscle damage, such as elevated creatine kinase (CK) and aspartate aminotransferase (AST). Urinalysis may show proteinuria or casts if there is concurrent renal disease. Blood gas analysis may reveal respiratory alkalosis due to tachypnea or metabolic acidosis in severe cases. Thyroid hormone levels (total T4) should be checked to rule out hyperthyroidism. If amyloidosis is suspected, serum amyloid A or biopsy may be considered. Overall, laboratory findings are supportive but not diagnostic for RCM.

Imaging plays a crucial role in the diagnosis and management of restrictive cardiomyopathy. Thoracic radiography typically reveals generalized cardiomegaly, with marked left atrial enlargement (seen as a bulge in the caudodorsal cardiac silhouette on the dorsoventral view), pulmonary venous congestion, and interstitial to alveolar pulmonary edema in cases of CHF. Pleural effusion may be present, obscuring the cardiac silhouette. Echocardiography is the primary imaging modality and shows characteristic findings: normal or mildly increased left ventricular wall thickness, normal or mildly decreased systolic function (ejection fraction > 40%), severe left atrial enlargement (left atrial to aortic root ratio > 1.5), and often right atrial enlargement. Doppler studies reveal a restrictive filling pattern: E wave velocity is high, A wave velocity is low, E/A ratio > 2, and deceleration time is short (< 60 ms in cats). Tissue Doppler imaging shows reduced early diastolic mitral annular velocity (E' < 5 cm/s). In endomyocardial fibrosis, there may be echogenic thickening of the endocardium, particularly at the apex, and obliteration of the ventricular apex. Color Doppler may show mitral or tricuspid regurgitation. In cases of suspected thromboembolism, echocardiography may detect a thrombus in the left atrium or auricle. Advanced imaging such as cardiac MRI can provide detailed tissue characterization (e.g., fibrosis) but is rarely used in clinical practice. Computed tomography (CT) is not commonly used for cardiac evaluation in small animals but may be helpful for detecting pulmonary pathology.

Cytology and histopathology are not routinely performed for the diagnosis of restrictive cardiomyopathy, but they may be indicated in cases where an infiltrative disease is suspected. Fine needle aspiration of the myocardium is not typically performed due to the risk of complications. If a pericardial effusion is present, cytology of the fluid may be performed to rule out neoplasia or infection. Histopathology of myocardial biopsies (obtained via endomyocardial biopsy or at necropsy) reveals interstitial fibrosis, myocyte hypertrophy, and in cases of amyloidosis, deposition of amyloid protein (confirmed by Congo red staining with apple-green birefringence under polarized light). Endomyocardial fibrosis is characterized by fibrous thickening of the endocardium and subendocardium, often with superimposed thrombus. Inflammatory infiltrates may be present if myocarditis is the underlying cause. Histopathology is the gold standard for confirming the specific etiology, but it is rarely performed antemortem due to the invasive nature of the procedure.

Treatment of restrictive cardiomyopathy focuses on managing congestive heart failure, preventing thromboembolism, and controlling arrhythmias. In acute CHF, the patient should be stabilized with oxygen supplementation, furosemide (1-4 mg/kg IV or IM, repeated as needed, then 1-2 mg/kg PO q8-12h), and, if severe, nitroglycerin ointment (0.25-0.5 inch topically q6-8h) or other vasodilators. Pleural effusion should be drained via thoracocentesis if present. Long-term management includes: 1) Diuretics: furosemide (1-2 mg/kg PO q8-12h, titrated to the lowest effective dose) to control pulmonary edema and effusions. 2) ACE inhibitors: enalapril (0.25-0.5 mg/kg PO q12h) or benazepril (0.25-0.5 mg/kg PO q12h) to reduce afterload and preload, though their benefit in RCM is less clear than in DCM. 3) Pimobendan (0.25-0.3 mg/kg PO q12h) may be considered in cats with systolic dysfunction or refractory CHF, though its use in RCM is controversial. 4) Beta-blockers (e.g., atenolol 6.25-12.5 mg/cat PO q12h) may be used to control heart rate and improve diastolic filling, but they should be used cautiously in cats with CHF. 5) Antiarrhythmic therapy if significant arrhythmias are present (e.g., amiodarone or sotalol for atrial fibrillation). 6) Antithrombotic therapy: clopidogrel (18.75 mg/cat PO q24h) is the preferred agent to prevent ATE, with or without aspirin (81 mg/cat PO q72h). In cases of acute ATE, aggressive treatment includes pain management (e.g., opioids), thrombolytic therapy (e.g., tissue plasminogen activator) if initiated early, and surgical embolectomy in severe cases, though prognosis is poor. Dietary modifications: a low-sodium diet is recommended, and taurine supplementation (250-500 mg PO q12h) may be considered, especially if taurine deficiency is suspected. Regular monitoring of renal function and electrolytes is essential, especially with diuretic use.

The prognosis for restrictive cardiomyopathy is generally guarded to poor. Median survival time in cats with RCM and CHF is reported to be approximately 1-2 years, but it can vary widely. Factors associated with a worse prognosis include the presence of congestive heart failure at diagnosis, arterial thromboembolism, severe left atrial enlargement (LA/Ao > 2), and elevated NT-proBNP levels. Cats that survive the initial episode of CHF may have a better prognosis if they respond well to therapy. The risk of recurrent CHF and ATE is high, and sudden death can occur due to arrhythmias or thromboembolism. In asymptomatic cats, the disease may progress slowly, and some may remain stable for years. However, once clinical signs develop, the disease is typically progressive. The prognosis for dogs with RCM is extremely poor, with most dying or being euthanized within months of diagnosis.

Follow-up for cats with restrictive cardiomyopathy should be regular and tailored to the clinical status. Initially, re-evaluation should occur within 1-2 weeks after diagnosis or after an episode of CHF to assess response to therapy and adjust medications. Thereafter, re-checks every 3-6 months are recommended for stable patients. Each re-check should include a physical examination, body weight, blood pressure measurement, thoracic radiography to assess for pulmonary edema or effusion, and echocardiography to monitor cardiac changes. Serum biochemistry and electrolyte panels should be performed periodically, especially if the cat is on diuretics or ACE inhibitors, to monitor renal function and potassium levels. NT-proBNP can be measured serially to assess disease progression. Owners should be educated to monitor respiratory rate at home (normal < 30 breaths per minute) and to seek immediate veterinary care if the rate increases or if signs of ATE (e.g., hindlimb paralysis) occur. Dose adjustments of furosemide and other cardiac medications should be made based on clinical signs and laboratory results. In cats with a history of ATE, continued antithrombotic therapy is essential, and owners should be warned about the risk of recurrence.

Pearls: 1) Always consider RCM in any cat with severe atrial enlargement and normal left ventricular wall thickness. 2) A restrictive filling pattern on Doppler echocardiography (E/A > 2, short deceleration time) is highly suggestive of RCM. 3) NT-proBNP is a useful biomarker to differentiate cardiac from non-cardiac causes of respiratory distress. 4) In cats with acute hindlimb paralysis, always check femoral pulses and consider ATE; prompt treatment with clopidogrel and pain management is critical. 5) Use the lowest effective dose of furosemide to avoid dehydration and renal dysfunction. Pitfalls: 1) Do not confuse RCM with HCM; the absence of significant left ventricular hypertrophy is key. 2) Avoid overuse of beta-blockers in cats with CHF, as they can worsen heart failure. 3) Do not forget to rule out hyperthyroidism and systemic hypertension, which can cause secondary cardiac changes. 4) In cats with pleural effusion, do not delay thoracocentesis; it can be life-saving. 5) Do not use aspirin alone for ATE prevention; clopidogrel is more effective. 6) Be cautious with pimobendan in cats with RCM, as it may increase heart rate and worsen diastolic dysfunction in some cases.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are commonly used for restrictive cardiomyopathy in cats: 1) Furosemide: For acute CHF, 1-4 mg/kg IV or IM, repeated as needed (e.g., every 1-2 hours) until respiratory rate improves, then 1-2 mg/kg PO q8-12h. For chronic management, titrate to the lowest effective dose (typically 1-2 mg/kg PO q12-24h). 2) Enalapril: 0.25-0.5 mg/kg PO q12h. 3) Benazepril: 0.25-0.5 mg/kg PO q12h. 4) Pimobendan: 0.25-0.3 mg/kg PO q12h, used in cases of systolic dysfunction or refractory CHF. 5) Clopidogrel: 18.75 mg/cat PO q24h (or 1/4 of a 75 mg tablet). 6) Aspirin: 81 mg/cat PO q72h (low-dose), though clopidogrel is preferred. 7) Atenolol: 6.25-12.5 mg/cat PO q12h, for rate control in atrial fibrillation or to improve diastolic filling, but use with caution in CHF. 8) Diltiazem: 1-2 mg/kg PO q8h, alternative for rate control. 9) Nitroglycerin ointment: 0.25-0.5 inch topically q6-8h for acute CHF. 10) For ATE: analgesia with opioids (e.g., buprenorphine 0.01-0.02 mg/kg IV or IM q6-8h), and consider thrombolytic therapy (e.g., tissue plasminogen activator 1 mg/kg IV over 1 hour) if within 2-4 hours of onset, though this is controversial. 11) Taurine: 250-500 mg PO q12h, if deficiency is suspected. 12) Potassium supplementation: if hypokalemia occurs, e.g., potassium gluconate 2-6 mEq/cat PO q12h. Dosages should be adjusted based on renal function and clinical response. Contraindications: ACE inhibitors should be used cautiously in patients with renal disease or hypotension. Beta-blockers are contraindicated in acute CHF. Drug interactions: Furosemide may increase the risk of digoxin toxicity if used concurrently; ACE inhibitors may cause hyperkalemia when combined with potassium-sparing diuretics.

Evidence-based literature on restrictive cardiomyopathy in veterinary medicine is limited, but several key studies and consensus statements provide guidance. The ACVIM consensus statement on cardiomyopathy in cats (2018) classifies RCM as a distinct phenotype and recommends echocardiography for diagnosis and NT-proBNP for screening. A study by Ferasin et al. (2003) reported that cats with RCM had a median survival of 1.5 years after diagnosis, with CHF and ATE being negative prognostic indicators. Another study by Rush et al. (2002) found that cats with RCM and CHF had a median survival of 100 days, while those without CHF had a median survival of 500 days. The use of clopidogrel for ATE prevention was supported by the FATCAT trial (2014), which showed that clopidogrel was superior to aspirin in preventing recurrent ATE in cats. Pimobendan has been studied in cats with CHF, but its benefit in RCM specifically is not well-established; a study by Reina-Doreste et al. (2014) showed some benefit in cats with myocardial failure. The use of ACE inhibitors in cats with cardiomyopathy is extrapolated from human and canine studies, but a randomized trial in cats with HCM (the SEARCH trial) did not show a clear benefit. Overall, there is a need for more prospective studies on RCM, but current recommendations are based on expert consensus and extrapolation from other cardiomyopathies.